British Medical Journal Concludes Depo-Provera Increases Risk of Brain Tumors

Publish Date : 09/27/2024

This 2024 national case-control study from France examined the risk of developing intracranial meningiomas associated with the use of specific progestogens, including Depo-Provera. The study included 18,061 women who underwent surgery for meningioma and compared them to 90,305 controls. Key findings are:

• Medrogestone, medroxyprogesterone acetate (injectable), and promegestone were associated with an increased risk of meningioma, especially with prolonged use (≥1 year).
• Cyproterone acetate, nomegestrol acetate, and chlormadinone acetate showed very high risks and were used as positive controls.

The study highlighted the increased risk with injectable medroxyprogesterone acetate, a common contraceptive.